These subjects received GS010 in one eye and a sham injection
in the other eye, with drug treatment randomized between best- and worst-affected eyes.
No animals in the sham injection
(vehicle only without STZ) died during the study period, regardless of their age at the time of injection (sixteen were 6-11 weeks old, four were 12-17 weeks old, and three were 18-23 weeks old).
Patients were randomly divided into 4 groups: sham injection
+ prompt laser, 0.5 mg intravitreal ranibizumab (IVR) + prompt laser, 0.5 mg IVR + deferred laser, and 4 mg IVTA + prompt laser.
Group 1 consisted of 8 rats, injected on day 0 and sacrificed on day 14; 3 received sham injection
, 5 received Botox[R] injection.
The multi-centre, double-masked, sham-controlled trial was designed to assess the safety and efficacy of aflibercept solution, with three quarters of patients receiving an injection of aflibercept solution and one quarter receiving a sham injection
. The trial's primary endpoint was the mean change at week 24 from baseline in best-corrected visual acuity as measured on the Early Treatment Diabetic Retinopathy Scale eye chart.
For experiments involving injections, three treatments were used: (1) intact controls (no injection), (2) sham injection
(injection of crustacean saline), and (3) injection of eyestalk extract.
Four to six months after the injection, the total number of hot flashes wasn't significantly different between the real- and sham-treated groups, but the number of moderate to severe hot flashes was cut in half for women who got the real nerve block (52 percent) compared with just 4 percent for the women who got the sham injection
In a randomized, 26-week, sham-controlled phase 3 trial, 229 eyes with noninfectious, intermediate, or posterior uveitis were randomized to a single treatment with a 700 [micro]g dexamethasone DDS (n = 77), a 350 [micro]g dexamethasone DDS (n = 76), or sham injection
(n = 76).
They received 0.3mg of either intravitreal pegaptanib or sham injection
every 6 weeks and were followed for 102 weeks.
After penetrating keratoplasty, Group A patients received subconjunctival bevacizumab (2.5 mg/ 0.1 ml), Group B, patients received sham injection
, while Group C patients received topical bevacizumab (2.5%, 25 mg/ml).
Bees that got IRS-inhibiting injections collected more pollen than bees given a sham injection